Contract Research Organization (CRO) industry: CRO demand recovery is strengthening, but valuations and structural mix pressures limit sector-wide upside

Overview

UBS takes a constructive view on improving CRO fundamentals, led by biotech funding, R&D growth and rising bookings, while remaining selective because FSP mix, AI-related long-term uncertainty and higher valuations constrain industry-wide upside. Its preferred ideas are IQVIA and Charles River Laboratories.

Core views

UBS expects global biopharma R&D spending to grow at a 5.2% CAGR from 2025 through 2030, versus 5.9% from 2010 through 2025. Small biotech is expected to lead reported R&D growth at 6.6%-6.7% annually, or 8.2% organically, followed by mid-sized biotech at 6.2% and large pharma at 4.3%. Adding zero to 100 basis points of outsourcing penetration to underlying R&D growth produces UBS's 5.2%-6.2% CRO market-growth range. This is below the industry's historical 7%-8% rate because the firm expects outsourcing to contribute less than before COVID, with 2027 R&D growth moderating to 4.8% from 6.0% in 2026E. The key near-term catalyst is biotech funding. Trailing-12-month funding was up 87% year on year through August, and UBS's historical analysis finds that funding direction is closely associated with CRO bookings and book-to-bill ratios. The clinical CRO group averaged a 1.23x book-to-bill ratio in 2Q26, with a 1.31x weighted average. Private-company checks indicate stronger bookings, with some private CROs above 2.0x book-to-bill, versus around or below 1.0x 12 to 18 months earlier. UBS therefore expects funding improvement, stronger biotech activity and stabilizing large-pharma development activity to support bookings in 2H26 and 1H27, although it notes 3Q26 RFP dollars were tracking about 10% below the 1H26 level at one CRO, attributed to seasonality. The report identifies FSP adoption as the principal structural constraint. In UBS's survey of 50 sponsors, 44% increased FSP use over the preceding 12 months, versus 24% increasing full-service outsourcing. Among large sponsors, 50% increased FSP use versus 25% for FSO. FSP leaves more trial management with sponsors, typically carries pricing 20%-30% below FSO and operating margins 300-500 basis points lower, so it can reduce both CRO revenue capture and profitability. UBS expects this effect to weigh on growth and margins for two to three years, even if the FSO/FSP mix begins to stabilize. It consequently expects revenue growth closer to mid-single digits rather than historical high-single digits and only flat to modest industry margin expansion beyond company-specific opportunities. AI is presented as a real but gradual long-term risk. It could reduce billable labor and revenue per trial, particularly in medical writing and biostatistics, which UBS estimates account for about 15% of a typical full-service Phase III study's revenue. Yet sponsors appear cautious about implementation, data quality and regulatory acceptance. In UBS's survey, 36% said AI would increase their inclination to outsource, 10% said it would decrease outsourcing, and 50% expected no effect. Forty-four percent expected AI to raise both the number and quality of molecules pursued, while 52% expected significant R&D savings only three or more years out. UBS therefore sees limited near-term earnings disruption, but considers AI a longer-term valuation overhang because it could lower terminal growth and revenue intensity. Valuation tempers the improving fundamental picture. CROs trade at about 22x NTM P/E, up from 15x in February, and at roughly 1.04x-1.10x the S&P 500 versus historical relative averages of 1.15x-1.30x. UBS believes better book-to-bill can support modest additional multiple expansion, but the sector's absolute valuation already exceeds its 19.5x post-GFC average and lower forward growth limits the runway. The firm uses P/E for most profitable, cash-generative CROs, but EV/EBITDA for leveraged Fortrea and clinical-technology company Certara. It favors firms with visible company-specific earnings drivers rather than broad sector exposure. IQVIA is UBS's top pick and is rated Buy with a $345 target based on 22x NTM+12-month P/E. UBS expects IQV's book-to-bill to rise from 1.22x in 2Q26 to 1.23x in 3Q26 and 1.25x in 4Q26, with FY27 at 1.23x versus consensus at 1.19x. That supports UBS estimates for Research & Development Solutions growth of 5.9% in FY26 and 6.2% in FY27, above consensus at 5.5% and 6.0%. Its survey placed IQV first in combined first- and second-choice CRO preferences at 22%, versus 13% for the next competitor. UBS also forecasts 20-30 basis points of annual margin improvement from scale and AI-related SG&A savings. At 19.6x NTM P/E, IQV trades below the 22x peer median and below its historical relative valuation. Charles River Laboratories is also rated Buy, with a $357 target based on 25x NTM+12-month P/E. UBS's central thesis is that internalizing non-human-primate supply through the KF acquisition can cut annualized sourcing costs by about $40 million by FY27, producing roughly $0.64 of EPS accretion and more than 160 basis points of Discovery and Safety Assessment operating-margin expansion. UBS estimates the NHP sourcing mix moves to 80% internal and 20% external, reducing annualized cost from roughly $155 million to $115 million. Better biotech demand supports a long-term DSA book-to-bill of about 1.15x, and modest study-price improvement is upside rather than a requirement. UBS's FY27 and FY28 adjusted EPS estimates are 5% and 8% above consensus, respectively, although it highlights CRL's 24x NTM P/E and elevated expectations as the principal risk. UBS is Neutral on ICLR despite its 15x NTM P/E and $195 target because client-specific challenges, FSP mix, pricing pressure and market-share uncertainty could constrain bookings and margins. It expects EBITDA margin to reach 17% by FY27 but does not expect a return to COVID-era 20%+ margins. MEDP is Neutral with a $673 target: its 95% biotech exposure gives it strong leverage to recovery, but its 33x NTM P/E, backlog coverage decline and booking volatility limit risk/reward. CERT is Neutral with a $10 target because UBS models only 7% long-term Software growth, around 2.5% Services growth and approximately 5% total growth; cost savings are partly offset by investments and stranded overhead, while AI-related demand is too early to underwrite. Fortrea is initiated at Neutral with a $22 target. UBS expects FY27 revenue growth of 2.2%, below consensus at 3.1%, and about 4% annual growth beginning in FY28, below its 5.2%-6.2% CRO industry outlook. FTRE reported a peer-low 1.06x book-to-bill in 2Q26; UBS forecasts 1.10x in 3Q26 and sees a sustained ratio nearer 1.20x as necessary to match industry growth. The company lacks an internal central lab, has lower-margin FSP work in backlog, faces possible large-client churn and has diminishing cost-cutting capacity. UBS expects EBITDA margin to reach nearly 10% by FY28 rather than the industry's mid-teens average. Deleveraging from current net leverage of 4.3x toward 2.5x-3.0x could be a positive catalyst, but the reported 12.6% LTM FCF yield is inflated by collections catch-up after an ERP-related invoicing disruption.

Analysis framework

UBS combines a model of R&D spending across 2,000 biopharma manufacturers, a proprietary survey of 50 sponsors, historical funding-to-bookings analysis, channel checks with public and private CROs, company discussions and peer valuation comparisons. It connects biotech funding and R&D budgets to bookings and book-to-bill, translates outsourcing mix into revenue and margin outcomes, then evaluates each company's market position, operating drivers, estimates and valuation.

Methodology notes

• Industry AnalysisSupply-demand framework

  Biopharma R&D and biotech funding are treated as demand drivers for CRO services, while outsourcing penetration determines how much spending reaches CROs.

  UBS bridges projected R&D growth and incremental outsourcing contribution to derive a 5.2%-6.2% CRO market-growth range.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Biotech funding is analyzed as a leading indicator that flows into sponsor R&D, CRO bookings, revenue growth and valuation.

  UBS uses historical trailing-12-month funding and booking comparisons to support its expectation of better bookings in 2H26 and 1H27.

• Valuation methodsP/E and PEG Valuation

  P/E multiples are used for most profitable CROs.

  UBS sets price targets using NTM+12-month P/E multiples and compares stocks with peer and historical relative P/E levels.

• Valuation methodsEV/EBITDA valuation

  EV/EBITDA is used for Fortrea because of leverage and Certara because it is a clinical-technology company.

  This metric incorporates debt and is used to set the FTRE and CERT price targets.

• Valuation methodsDCF (Discounted Cash Flow)

  Reverse DCF analysis infers the growth and margin assumptions embedded in market valuations.

  UBS compares implied 10-year revenue-growth and margin assumptions with its own forecasts and consensus expectations.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• IQVIA (IQV)

  Preferred CRO exposure to improving biotech demand and bookings

  Strengths

  Expected sustained book-to-bill above 1.20x, survey-leading CRO preference, share-gain evidence, scale and potential AI-driven SG&A savings.

  Weaknesses

  Commercial Solutions organic growth is modeled at about 4% annually.

  Comparison

  19.6x NTM P/E versus the CRO peer median of 22x; relative P/E of 0.85x versus a 0.97x historical average.

  Risks

  FSP mix and sponsor insourcing could limit gross-margin improvement.

• Charles River Laboratories (CRL)

  Preferred preclinical CRO exposure with a company-specific margin catalyst

  Strengths

  KF acquisition is expected to internalize NHP supply and generate about $40M annualized savings, $0.64 EPS accretion and 160bps+ DSA margin expansion.

  Weaknesses

  Earnings thesis depends on realizing internal-sourcing savings.

  Comparison

  Trades at 24x NTM P/E versus a CRO peer median of 20x.

  Risks

  Premium valuation and elevated expectations leave less room for execution shortfalls.

• ICON Plc (ICLR)

  Covered clinical CRO

  Strengths

  Low valuation and UBS expectation for EBITDA margin to return to 17% by FY27.

  Weaknesses

  Client challenges, FSP mix, pricing pressure and uncertain market-share recovery.

  Comparison

  15x NTM P/E, below the 22x CRO peer median.

  Risks

  Bookings and EBITDA estimates face incremental risk in 2H26 and FY27.

• Medpace (MEDP)

  Covered biotech-focused clinical CRO

  Strengths

  95% biotech revenue exposure and potential to sustain roughly 9% long-term revenue growth.

  Weaknesses

  Reported backlog has stalled while revenue has risen, increasing reliance on pre-backlog conversion.

  Comparison

  33x NTM P/E, the highest CRO valuation in the group.

  Risks

  Booking volatility and a failure to replenish backlog could cause a material revenue slowdown.

• Fortrea (FTRE)

  Covered clinical CRO; initiated at Neutral

  Strengths

  Potential deleveraging as free cash flow normalizes and new leadership provides a clearer strategy.

  Weaknesses

  Softer bookings, market-share pressure, lack of an internal central lab, FSP-heavy backlog and diminishing cost savings.

  Comparison

  11.7x NTM EV/EBITDA, an industry low and broadly in line with its historical relative valuation.

  Risks

  Potential client churn, elevated leverage and inability to sustain book-to-bill near 1.20x.

• Certara (CERT)

  Covered clinical-technology company

  Strengths

  Biosimulation and Model-Informed Drug Development capabilities; potential AI-related awareness benefit.

  Weaknesses

  Limited visibility into Software adoption and margin expansion; UBS models only 7% long-term Software growth.

  Comparison

  Target is based on 13x NTM+12-month EV/EBITDA, in line with current valuation and the ClinTech peer median.

  Risks

  Cost savings may be offset by investment and stranded overhead; AI demand contribution is too early to underwrite.

Key data

• Global biopharma R&D growth5.2% CAGR, 2025-2030Versus 5.9% CAGR from 2010-2025.
• CRO market-growth outlook5.2%-6.2% per year through 2030Includes zero to 100 basis points of outsourcing contribution.
• TTM biotech funding+87% year on year through AugustUBS views funding as a leading indicator for CRO bookings.
• Clinical CRO book-to-bill1.23x average; 1.31x weighted average in 2Q26Bookings and book-to-bill are key industry valuation indicators.
• CRO valuation~22x NTM P/EUp from 15x in February and above the 19.5x post-GFC average.
• FSP economics20%-30% lower pricing and 300-500bps lower operating margins than FSOSupports UBS's cautious view on structural revenue and margin capture.
• CRL NHP internalization savings~$40M annualized by FY27UBS estimates ~$0.64 EPS accretion and 160bps+ DSA margin expansion.

Impact & implications

UBS expects better CRO bookings to support a revenue-growth recovery, but believes the sector is unlikely to regain historical high-single-digit growth because FSP mix reduces revenue capture and margins. The firm therefore favors IQV for expected share gains and a discounted valuation, and CRL for a visible internal-sourcing earnings catalyst, while viewing the other covered names as more balanced or constrained by execution and valuation.

Risks

• Adverse clinical-trial results, biotech-funding volatility and changes in biopharma R&D budgets could weaken CRO demand.
• Evolving pharmaceutical regulation, including FDA-related uncertainty, could affect development activity.
• Geopolitical disruptions could affect research sites, funding or development activity.
• A continued shift toward FSP could pressure CRO revenue growth, pricing and margins.
• AI could eventually reduce revenue per trial and commoditize certain CRO services.

What to watch

• Whether biotech funding remains strong enough to sustain improving CRO bookings and book-to-bill in 2H26 and 1H27.
• The balance between FSO and FSP adoption, especially among large pharmaceutical sponsors.
• Whether private and public CRO booking improvement converts into revenue growth as backlog burns.
• IQV's ability to sustain book-to-bill above 1.20x and gain share.
• CRL's realization of NHP sourcing savings and DSA-margin expansion.
• FTRE's bookings, revenue inflection, margin improvement and deleveraging progress.